These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Combined therapy for stage IIIa non-small cell lung cancer].
    Author: Zhao LQ, Hou SC, Li H, Hu B, Wang Y.
    Journal: Zhonghua Yi Xue Za Zhi; 2005 Aug 03; 85(29):2030-2. PubMed ID: 16313794.
    Abstract:
    OBJECTIVE: To evaluate the long-term outcome of combined therapy for stage IIIa non-small cell lung cancer (NSCLC). METHODS: Eight and twelve patients with stage IIIa NSCLC, 662 males and 150 females, aged 58.6 (24-79), underwent surgical resection, 326 of which received pre- and postoperative chemotherapy and/or radiotherapy, and 486 of which received surgery alone. The patients were classified according to the TNM staging, and the specimens of resected cancer were examined pathologically. The clinical data of these patients were analyzed. RESULTS: The overall 5-year survival rate was 16.4%. The 5-year survival rate of the combined therapy group was 23.5%, significantly higher than that of the surgical resection alone group (P < 0.01). The 5-year survival rate was 27.6% for the squamous cell carcinoma (SCC), and 23.5% for adenocarcinoma (AC) in the combined therapy group; and was 115.2% for SCC and 9.9% for AC in the surgical resection alone group (all P < 0.01). CONCLUSION: The curative effectiveness of combined therapy is significantly better than surgical resection alone for stage IIIa NSCLC. However, The combination should be based on the TNM staging and pathological type.
    [Abstract] [Full Text] [Related] [New Search]